Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2000

View Archived Issues

BioPulse and Brigham Young partner on major cancer diagnostic breakthrough

PathoGenome database utilized for antiinfective drug discovery

Eisai responsible for Japanese development, marketing of botulinum toxin type B

Conformationally constrained butyrophenones as potential antipsychotic agents

Cellegy begins expanded phase I/II trial with Tostrelle; new collaboration on FSD announced

Alza licenses dapoxetine from PPD GenuPro

Ranolazine enters phase II for CHF

Apthera for canker sores approved in Canada

Phenserine enters phase II trial for Alzheimer's disease

Anti-IL-9 antibody collaboration terminated by Genentech

York Medical changes name, reports pipeline progress

VX-148 enters clinical development

Potent, selective proteasome compounds derived from belactosin

Mitsubishi-Tokyo stops development of antidepressant MCI-225

Development of MKC-542 under consideration at Mitsubishi-Tokyo

TKT reacquires rights to second Gene-Activated Protein from Aventis

Preclinical trials with decitabine suggest potential in myelodysplastic syndrome, multiple myeloma

Schering-Plough to market pranlukast in Latin America

Potential of tegaserod in GERD therapy indicated by recent clinical study findings

Spanish researchers claim novel antiviral agents

Taisho presents new compounds with potential in the treatment of renal and cardiovascular conditions

Pyrazole derivatives from Yamanouchi inhibit CRACC and IL-2 production

Recent patent covers new GnRH antagonists prepared by Merck scientists

Prostaglandin analogues for glaucoma, ocular hypertension described in December patent

New oncolytic drugs from Schering-Plough act by inhibiting protein farnesyltransferase

Dual inhibitors of ACE/NEP in development at Toa Eiyo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.